Total Payments
$523,807
2024 Payments
$8,414
Companies
31
Transactions
1,060
Medicare Patients
334
Medicare Billing
$171,728
Payment Breakdown by Category
Other$411,928 (78.6%)
Consulting$52,867 (10.1%)
Travel$31,819 (6.1%)
Food & Beverage$25,685 (4.9%)
Research$1,016 (0.2%)
Education$492.08 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $411,886 | 230 | 78.6% |
| Consulting Fee | $52,867 | 25 | 10.1% |
| Travel and Lodging | $31,819 | 125 | 6.1% |
| Food and Beverage | $25,685 | 667 | 4.9% |
| Unspecified | $1,016 | 2 | 0.2% |
| Education | $492.08 | 10 | 0.1% |
| Grant | $41.50 | 1 | 0.0% |
Payments by Type
General
$522,791
1,058 transactions
Research
$1,016
2 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Amgen Inc. | $124,223 | 175 | $0 (2023) |
| Allergan, Inc. | $115,279 | 191 | $0 (2021) |
| Teva Pharmaceuticals USA, Inc. | $111,148 | 195 | $0 (2023) |
| ABBVIE INC. | $49,968 | 72 | $0 (2024) |
| Lilly USA, LLC | $32,220 | 59 | $0 (2022) |
| Supernus Pharmaceuticals, Inc. | $24,343 | 105 | $0 (2019) |
| Biohaven Pharmaceuticals, Inc. | $21,717 | 34 | $0 (2021) |
| Avanir Pharmaceuticals, Inc. | $18,676 | 43 | $0 (2018) |
| Biohaven Pharmaceutical Holding Company Ltd. | $14,252 | 19 | $0 (2022) |
| Promius Pharma LLC | $4,839 | 20 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $8,414 | 23 | ABBVIE INC. ($7,846) |
| 2023 | $17,250 | 30 | AbbVie Inc. ($16,706) |
| 2022 | $27,259 | 44 | Biohaven Pharmaceutical Holding Company Ltd. ($14,252) |
| 2021 | $66,235 | 86 | Biohaven Pharmaceuticals, Inc. ($21,671) |
| 2020 | $114,567 | 123 | Allergan, Inc. ($52,900) |
| 2019 | $112,293 | 209 | Amgen Inc. ($44,855) |
| 2018 | $119,241 | 288 | Amgen Inc. ($52,307) |
| 2017 | $58,548 | 257 | Avanir Pharmaceuticals, Inc. ($18,604) |
All Payment Transactions
1,060 individual payment records from CMS Open Payments — Page 1 of 43
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | ABBVIE INC. | UBRELVY (Drug) | Consulting Fee | Cash or cash equivalent | $393.75 | General |
| Category: NEUROSCIENCE | ||||||
| 12/04/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $25.05 | General |
| Category: PAIN | ||||||
| 11/16/2024 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $37.33 | General |
| Category: NEUROSCIENCE | ||||||
| 11/15/2024 | PFIZER INC. | NURTEC ODT (Drug) | Food and Beverage | In-kind items and services | $132.15 | General |
| Category: PAIN | ||||||
| 11/14/2024 | Tonix Medicines, Inc. | ZEMBRACE SYMTOUCH (Drug) | Food and Beverage | In-kind items and services | $95.75 | General |
| Category: NEUROLOGY | ||||||
| 11/14/2024 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $33.57 | General |
| Category: NEUROSCIENCE | ||||||
| 10/28/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $12.49 | General |
| Category: PAIN | ||||||
| 09/24/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $22.64 | General |
| Category: PAIN | ||||||
| 08/14/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $26.37 | General |
| Category: PAIN | ||||||
| 08/12/2024 | ABBVIE INC. | — | Consulting Fee | Cash or cash equivalent | $1,837.50 | General |
| 07/29/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $14.44 | General |
| Category: PAIN | ||||||
| 07/12/2024 | ABBVIE INC. | QULIPTA (Drug), BOTOX | Food and Beverage | In-kind items and services | $25.31 | General |
| Category: NEUROSCIENCE | ||||||
| 07/02/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $13.85 | General |
| Category: PAIN | ||||||
| 06/18/2024 | ABBVIE INC. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,625.00 | General |
| 05/29/2024 | PFIZER INC. | NURTEC ODT (Drug) | Food and Beverage | In-kind items and services | $24.39 | General |
| Category: PAIN | ||||||
| 05/16/2024 | ABBVIE INC. | — | Food and Beverage | In-kind items and services | $125.01 | General |
| 05/16/2024 | ABBVIE INC. | — | Travel and Lodging | In-kind items and services | $38.86 | General |
| 05/07/2024 | ABBVIE INC. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,625.00 | General |
| 04/17/2024 | ABBVIE INC. | — | Food and Beverage | In-kind items and services | $72.95 | General |
| 04/02/2024 | Tonix Medicines, Inc. | ZEMBRACE SYMTOUCH (Drug) | Food and Beverage | In-kind items and services | $105.63 | General |
| Category: NEUROLOGY | ||||||
| 03/09/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $70.53 | General |
| Category: PAIN | ||||||
| 03/09/2024 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $31.43 | General |
| Category: NEUROSCIENCE | ||||||
| 03/07/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $24.50 | General |
| Category: PAIN | ||||||
| 11/17/2023 | Amgen Inc. | Aimovig (Biological) | Food and Beverage | In-kind items and services | $143.25 | General |
| Category: Neuroscience | ||||||
| 11/17/2023 | AbbVie Inc. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $120.57 | General |
| Category: NEUROSCIENCE | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 23, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL AGN-241689 IN EPISODIC MIGRAINE PREVENTION. | Allergan Inc. | $1,016 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 94 | 7,326 | $161,740 | $46,384 |
| 2022 | 5 | 104 | 5,623 | $139,650 | $38,480 |
| 2021 | 4 | 70 | 7,010 | $145,250 | $40,915 |
| 2020 | 4 | 66 | 7,783 | $97,856 | $45,949 |
Total Patients
334
Total Services
27,742
Medicare Billing
$171,728
Procedure Codes
18
All Medicare Procedures & Services
18 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0585 | Injection, onabotulinumtoxina, 1 unit | Office | 2023 | 11 | 7,200 | $100,800 | $33,115 | 32.9% |
| 64615 | Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face | Office | 2023 | 16 | 47 | $33,135 | $5,771 | 17.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 40 | 51 | $19,125 | $5,272 | 27.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 16 | 17 | $4,335 | $1,165 | 26.9% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 11 | 11 | $4,345 | $1,061 | 24.4% |
| J0585 | Injection, onabotulinumtoxina, 1 unit | Office | 2022 | 11 | 5,491 | $75,460 | $23,909 | 31.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 39 | 56 | $21,000 | $5,777 | 27.5% |
| 64615 | Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face | Office | 2022 | 12 | 33 | $23,265 | $4,096 | 17.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 28 | 28 | $16,100 | $3,602 | 22.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 14 | 15 | $3,825 | $1,095 | 28.6% |
| J0585 | Injection, onabotulinumtoxina, 1 unit | Office | 2021 | 13 | 6,920 | $96,880 | $30,179 | 31.2% |
| 64615 | Injection of chemical for destruction of facial and neck nerve muscles on both sides of face | Office | 2021 | 12 | 34 | $23,970 | $4,175 | 17.4% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 28 | 39 | $14,625 | $4,061 | 27.8% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 17 | 17 | $9,775 | $2,500 | 25.6% |
| J0585 | Injection, onabotulinumtoxina, 1 unit | Office | 2020 | 14 | 7,700 | $70,000 | $37,298 | 53.3% |
| 64615 | Injection of chemical for destruction of facial and neck nerve muscles on both sides of face | Office | 2020 | 15 | 44 | $19,100 | $5,685 | 29.8% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 22 | 23 | $6,218 | $2,040 | 32.8% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 15 | 16 | $2,538 | $925.82 | 36.5% |
About Dr. Tanya Bilchik, MD
Dr. Tanya Bilchik, MD is a Neurology healthcare provider based in East Hartford, Connecticut. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/14/2006. The National Provider Identifier (NPI) number assigned to this provider is 1881668101.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Tanya Bilchik, MD has received a total of $523,807 in payments from pharmaceutical and medical device companies, with $8,414 received in 2024. These payments were reported across 1,060 transactions from 31 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($411,886).
As a Medicare-enrolled provider, Bilchik has provided services to 334 Medicare beneficiaries, totaling 27,742 services with total Medicare billing of $171,728. Data is available for 4 years (2020–2023), covering 18 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Location East Hartford, CT
- Active Since 02/14/2006
- Last Updated 07/08/2007
- Taxonomy Code 2084N0400X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1881668101
Products in Payments
- Aimovig (Biological) $105,035
- UBRELVY (Drug) $76,445
- AJOVY (Drug) $52,986
- AJOVY (Biological) $49,187
- BOTOX (Biological) $38,357
- NURTEC ODT (Drug) $36,633
- TROKENDI XR (Drug) $24,343
- EMGALITY (Drug) $22,915
- BOTOX (Drug) $20,365
- ONZETRA Xsail (Drug) $17,759
- Zembrace (Drug) $4,812
- QULIPTA (Drug) $4,142
- TREXIMET (Drug) $3,568
- BOTOX CHRONIC MIGRAINE (Drug) $3,516
- REYVOW (Drug) $2,813
- NUEDEXTA (Drug) $916.17
- Trudhesa (Drug) $897.43
- COPAXONE (Drug) $417.63
- Cambia (Drug) $341.74
- BOTOX THERAPEUTIC (Biological) $282.91
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.